Naperville, IL -- (SBWIRE) -- 10/02/2014 -- Reportstack, provider of premium market research reports announces the addition of PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023 market report to its offering
PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023
Summary
Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
The 2013 base-year market sales of asthma products in France were $918m.The relatively slow growth of the German market compared with the French, Spanish, and UK markets is attributable to the slightly decreasing prevalence of asthma in this country over the forecast period. . Advairs active patent on the Diskus delivery platform in Italy has already expired, but still generates high sales numbers due to the difficulties involved in replicating the delivery technology. The publisher believes that Advair will slowly lose its dominant position in the Spanish market. The publisher expects Breo Ellipta to dominate the branded segment of the UK ICS/LABA market, as it is the first complete regimen to be dosed once daily for asthma treatment.
Scope
- Overview of Asthma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU (the UK, France, Italy, Spain, Germany) from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Asthma market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Asthma.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of drug performance.
- Obtain sales forecast for drugs from 2013-2023 in 5EU (the UK, France, Italy, Spain, Germany).
To view the table of contents for this market research report please visit
http://www.reportstack.com/product/174620/pharmapoint-asthma-5eu-drug-forecast-and-market-analysis-to-2023.html
Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604